Accelerating Medicines Partnership® SCHIZOPHRENIA
For Scientists
Using data from a non-interventional study, the Accelerating Medicines Partnership (AMP®) SCZ program seeks to build tools to improve success in developing pharmacologic treatments for patients with clinical high risk for psychosis.

Data Sharing

An important component of the Accelerating Medicines Partnership (AMP®) SCZ program is the rapid dissemination of research data and analysis pipelines to the research community.

The AMP SCZ program data will be uploaded to the National Institute of Mental Health (NIMH) Data Archive (NDA), which will provide cloud-based infrastructure to support data storage. The NDA currently holds raw and processed data (including clinical, biological, genetic and outcome measures) from approximately 500,000 research participants.

The AMP SCZ program data will be available to the larger research community for further study. All AMP SCZ program data stored in the NDA will adhere to the NDA terms and conditions and the NIMH Data Sharing Policy. Specifically, participant data will be aggregated in a privacy-enabled manner and will be protected by practices that include the removal of any personal identifiable information; accredited users will be given secure, role-based access to the data.

The archive includes data dictionaries to describe and enable efficient searches across the diverse types of data. These data dictionaries will also be used in data acquisition forms, which will facilitate the flow of data from the research networks to the DPACC for data capture, processing, and analyses.

Qualified researchers can request access to data hosted on the NDA. If you are interested in accessing the data hosted on the NDA you must register for an NDA account and submit a request, including a research-related need to access the data and a data use certification signed by you and your institution.

Last Reviewed on May 2, 2022